PL441643A1 - Sposób różnicowania łagodnych i złośliwych guzków tarczycy - Google Patents

Sposób różnicowania łagodnych i złośliwych guzków tarczycy

Info

Publication number
PL441643A1
PL441643A1 PL441643A PL44164322A PL441643A1 PL 441643 A1 PL441643 A1 PL 441643A1 PL 441643 A PL441643 A PL 441643A PL 44164322 A PL44164322 A PL 44164322A PL 441643 A1 PL441643 A1 PL 441643A1
Authority
PL
Poland
Prior art keywords
genes
thyroid
benign
thyroid nodules
malignant
Prior art date
Application number
PL441643A
Other languages
English (en)
Inventor
Sebastian Student
Tomasz TYSZKIEWICZ
Michał JARZĄB
Dorota Słowińska-Klencka
Dagmara RUSINEK
Jolanta Krajewska
Agata Wilk
Krzysztof Łakomiec
Jadwiga Żebracka
Alicja Płuciennik
Krzysztof Fujarewicz
Rafał Tarnawski
Małgorzata OCZKO-WOJCIECHOWSKA
Barbara JARZĄB
Original Assignee
Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie-Państwowy Instytut Badawczy Oddział W Gliwicach
Politechnika Śląska
Polskie Towarzystwo Endokrynologiczne
Uniwersytet Medyczny w Łodzi
Wasko Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie-Państwowy Instytut Badawczy Oddział W Gliwicach, Politechnika Śląska, Polskie Towarzystwo Endokrynologiczne, Uniwersytet Medyczny w Łodzi, Wasko Spółka Akcyjna filed Critical Narodowy Instytut Onkologii Im. Marii Skłodowskiej-Curie-Państwowy Instytut Badawczy Oddział W Gliwicach
Priority to PL441643A priority Critical patent/PL441643A1/pl
Publication of PL441643A1 publication Critical patent/PL441643A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób różnicowania łagodnych i złośliwych guzków tarczycy w materiale z biopsji guza, sklasyfikowanej zgodnie z systemem Bethesda, który obejmuje etapy izolacji RNA, oraz określenie poziomu ekspresji zestawu genów, który obejmuje: AMOT, C3, CAMK2N1, CFI, DCSTAMP, DIO1, DUSP5, EGR1, EMP2, FAM20A, FAXC, FLRT3, HBG1, IGFBP6, IGSF1, ITGA2, KCNQ3, MET, METTL7B, MPZL2, NOD1, OLR1, PDE5A, PSD3, SDC4, SLC26A4, SLC26A7, SLC5A8, SLPI, TM4SF1, TPO, TUSC3. Normalizację ekspresji 32 genów tego zestawu prowadzi się pod endogenną kontrolą co najmniej czterech genów normalizujących spośród EIF3A (EIF3S10), HADHA, UBE2D2, EIF5, PPIE oraz RPLPO. Do różnicowania guzków tarczycy wykorzystuje się algorytm klasyfikatora, który nauczony jest na danych ekspresji genów skorelowanych z charakterem guzka tarczycy, zwłaszcza łagodnych guzków tarczycy i nowotworu złośliwego, w tym raka brodawkowatego i pęcherzykowego tarczycy.
PL441643A 2022-07-05 2022-07-05 Sposób różnicowania łagodnych i złośliwych guzków tarczycy PL441643A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL441643A PL441643A1 (pl) 2022-07-05 2022-07-05 Sposób różnicowania łagodnych i złośliwych guzków tarczycy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441643A PL441643A1 (pl) 2022-07-05 2022-07-05 Sposób różnicowania łagodnych i złośliwych guzków tarczycy

Publications (1)

Publication Number Publication Date
PL441643A1 true PL441643A1 (pl) 2024-01-08

Family

ID=89473648

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441643A PL441643A1 (pl) 2022-07-05 2022-07-05 Sposób różnicowania łagodnych i złośliwych guzków tarczycy

Country Status (1)

Country Link
PL (1) PL441643A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2569626A2 (en) * 2010-05-11 2013-03-20 Veracyte, Inc. Methods and compositions for diagnosing conditions
WO2013138726A1 (en) * 2012-03-15 2013-09-19 Sabiosciences Corp. Thyroid cancer biomarker
US20170329894A1 (en) * 2008-11-17 2017-11-16 Veracyte, Inc. Algorithms for disease diagnostics
EP3467123A2 (en) * 2008-11-17 2019-04-10 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170329894A1 (en) * 2008-11-17 2017-11-16 Veracyte, Inc. Algorithms for disease diagnostics
EP3467123A2 (en) * 2008-11-17 2019-04-10 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
EP2569626A2 (en) * 2010-05-11 2013-03-20 Veracyte, Inc. Methods and compositions for diagnosing conditions
WO2013138726A1 (en) * 2012-03-15 2013-09-19 Sabiosciences Corp. Thyroid cancer biomarker

Similar Documents

Publication Publication Date Title
Bayarri-Lara et al. Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection
Aerts et al. Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR
Su et al. Molecular classification of human carcinomas by use of gene expression signatures
Oien et al. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling
US20200202974A1 (en) Algorithms for disease diagnostics
US20140178874A1 (en) Method for evaluating cancer
Prabakaran et al. Gaussian mixture models for probabilistic classification of breast cancer
EP3467123A2 (en) Methods and compositions of molecular profiling for disease diagnostics
US20070231822A1 (en) Methods for the detection and treatment of cancer
Martens et al. DNA methylation as a biomarker in breast cancer
AU2017268578B2 (en) Methods and compositions of molecular profiling for disease diagnostics
Reiman et al. Integrating RNA expression and visual features for immune infiltrate prediction
Brogna et al. Evaluation and Comparison of Prognostic Multigene Tests in Early‐Stage Breast Cancer: Which Is the Most Effective? A Literature Review Exploring Clinical Utility to Enhance Therapeutic Management in Luminal Patients
PL441643A1 (pl) Sposób różnicowania łagodnych i złośliwych guzków tarczycy
AU2017261688B2 (en) Methods and materials for staging and treating skin cancer
Whipple et al. A genomic predictor of oral squamous cell carcinoma
Yang et al. PreCanCell: An ensemble learning algorithm for predicting cancer and non-cancer cells from single-cell transcriptomes
US20170183738A1 (en) Process, Apparatus or System and Kit for Classification of Tumor Samples of Unknown and/or Uncertain Origin and Use of Genes of the Group of Biomarkers
Igci et al. Differential expression of a set of genes in follicular and classic variants of papillary thyroid carcinoma
Jeske et al. Two-stage classifiers that minimize PCA3 and the PSA proteolytic activity testing in the prediction of prostate cancer recurrence after radical prostatectomy
Gonçalves-Reis et al. Analytical validation and algorithm improvement of HepatoPredict kit to assess hepatocellular carcinoma prognosis before a liver transplantation
CN115369173A (zh) 基因标志物组合在预测膀胱尿路上皮癌预后中的应用
PL441645A1 (pl) Sposób odróżniania złośliwych i łagodnych guzków tarczycy
Zannoni et al. HER2 in Gynecological Malignancies: Bridging the Gap Between Standardized Pathological Assessment and Precision Therapy
Dermawan Methylation Profiles in Bone and Soft Tissue Tumors: Do They Help Classify the Unclassifiable?